Erelzi and Chronic obstructive pulmonary disease - a phase IV clinical study of FDA data

Summary:

Chronic obstructive pulmonary disease is reported as a side effect among people who take Erelzi (etanercept-szzs), especially for people who are female, 60+ old, have been taking the drug for 1 - 6 months also take Sulfasalazine, and have Rheumatoid arthritis.

The phase IV clinical study analyzes which people have Chronic obstructive pulmonary disease when taking Erelzi. It is created by eHealthMe based on reports of 11,624 people who have side effects when taking Erelzi from the FDA, and is updated regularly.

What is Erelzi?

Erelzi has active ingredients of etanercept-szzs. eHealthMe is studying from 11,625 Erelzi users. Check the latest studies of Erelzi.

What is Chronic obstructive pulmonary disease?

Chronic obstructive pulmonary disease (a progressive disease that makes it hard to breathe) is found to be associated with 1,807 drugs and 2,206 conditions by eHealthMe. Check the latest studies of Chronic obstructive pulmonary disease.

On Jul, 16, 2026

11,624 people reported to have side effects when taking Erelzi.
Among them, 87 people (0.75%) have Chronic obstructive pulmonary disease.

Could Erelzi cause Chronic obstructive pulmonary disease?

Among these 87 people:

How long have people been on Erelzi when they have Chronic obstructive pulmonary disease? *

What is the gender of people who have Chronic obstructive pulmonary disease when taking Erelzi? *

female: 86.21 %
male: 13.79 %

What is the age of people who have Chronic obstructive pulmonary disease when taking Erelzi? *

What are other drugs people take besides Erelzi? *

What are other side effects people have besides Chronic obstructive pulmonary disease? *

Diarrhea: 33 people, 37.93%
Dyspnea (difficult or laboured breathing): 30 people, 34.48%
Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 30 people, 34.48%
Lower Respiratory Tract Infection: 26 people, 29.89%
Fall: 25 people, 28.74%
Pain: 25 people, 28.74%
Constipation: 25 people, 28.74%
Hepatic Steatosis (fatty liver disease): 25 people, 28.74%
Pneumonia: 24 people, 27.59%
Abdominal Pain: 21 people, 24.14%

What are the existing conditions these people have? *

Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 71 people, 81.61%
Osteoporosis (bones weak and more likely to break): 21 people, 24.14%
Osteoarthritis (a joint disease caused by cartilage loss in a joint): 21 people, 24.14%
Myocardial Ischaemia (the blood flow through one or more of the blood vessels that lead to heart (coronary arteries) is decreased): 21 people, 24.14%
Mania (a state of abnormally elevated or irritable mood): 21 people, 24.14%
High Blood Pressure: 21 people, 24.14%
Oesophagitis Ulcerative (inflammation of oesophagus with multiple ulcers): 20 people, 22.99%
Psoriatic Arthropathy (inflammation of the skin and joints with kin condition which typically causes patches (plaques) of red, scaly skin to develop): 13 people, 14.94%
Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 5 people, 5.75%
Psoriasis (immune-mediated disease that affects the skin): 4 people, 4.60%

* Approximation only. Some reports may have incomplete information.

Do you take Erelzi and have Chronic obstructive pulmonary disease?

- Check whether Chronic obstructive pulmonary disease is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Erelzi:

Erelzi (11,625 reports)

Browse all side effects of Erelzi:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Chronic obstructive pulmonary disease:

Chronic obstructive pulmonary disease (1,807 drugs)

Browse all the conditions that are associated with Chronic obstructive pulmonary disease:

Chronic obstructive pulmonary disease (2,206 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on etanercept-szzs (the active ingredients of Erelzi) and Erelzi (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.